

May 21, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Subject: Press Release and Investor Presentation for FY 2024-25

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release and Investor Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**

Yoshita Vora

Company Secretary & Compliance Officer

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

SeQuent growth continues to accelerate

Q4 FY25 – Revenues at ₹ 4,017 Million up by 11.2%, EBITDA at ₹ 569 Million up 38.7%

FY25 – Revenues at ₹ 15,514 Million up by 13.3%, EBITDA at ₹ 1,993 Million up 86.6%

Mumbai, May 20, 2025

SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health Formulations and APIs announced its financial results today for the quarter and year March 31, 2025

Consolidated Financial Highlights

₹ in millions

	Q4FY25	Q4FY24	Growth %	FY25	FY24	Growth %
Revenues	4,017	3,612	11.2%	15,514	13,697	13.3%
EBITDA	569	411	38.7%	1,993	1,068	86.6%
Margins	14.2%	11.4%	280 bps	12.8%	7.8%	500 bps

Detailed presentation on the performance forms part of this press release

Commenting on the Company’s performance, **Rajaram Narayanan, Managing Director** stated “This quarter reinforces the momentum that we have built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back of several initiatives which have helped deliver a superior product mix, accelerate launches and improve operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning point for us, as we prepare to accelerate the growth of the company and create the foundation for the Sequent 3.0 journey.”

Earnings Call with Investors

The Company will conduct an Earnings call at **9:00 AM IST on May 21, 2025** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) corporate office in Mumbai, India with a global footprint, operates in the domains of Formulations and APIs. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact

Yoshita Vora

Company Secretary, Tel: +91 22 4111 4717
investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultants
abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli's Corporate,
Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,
Shaikpet, Hyderabad-500033, Telangana
CIN: L99999TS1985PLC196357
BSE Code: 512529 I NSE: SEQUENT
ISIN: INE807F01027 I REUTERS: EQU.BO
Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance



INVESTOR PRESENTATION

Q4 FY25

SEQUENT SCIENTIFIC LIMITED

20th May 2025

Steadfast Commitment to Improvement in Business Fundamentals

“This quarter reinforces the momentum that we have built in the business over the last 18 months. The significant improvement in profitability metrics and double-digit revenue growth has come on the back of several initiatives which have helped deliver a superior product mix, accelerate launches and improve operational efficiency. Our proposed merger with Viyash Life Sciences is proceeding on plan. The strong performance in FY 24-25 marks a turning point for us, as we prepare to accelerate the growth of the company and create the foundation for the Sequent 3.0 journey.”

Rajaram Narayanan

Managing Director and CEO




SeQuent & Viyash :

Proforma Q4FY25 Combined Performance




Q4 FY25 Performance Highlights (Combined)

All values in ₹ Mn



FY25 Performance Highlights (Combined)

All values in ₹ Mn



SeQuent : Q4FY25 Performance Update



Strong profitable business growth continues in Q4FY25

All values in ₹ Mn


Revenues



Adj. EBITDA¹



Adj. EBITDA margin



PAT



Note: 1. EBITDA for SeQuent is adjusted for ESOP Costs

FY25: Closed the year with healthy double-digit profitable growth

All values in ₹ Mn




Revenues




Adj. EBITDA¹



Adj. EBITDA margin



Net Debt to LTM Adj. EBITDA¹



Note: 1. EBITDA for SeQuent is adjusted for ESOP Costs

Revenue Performance – by Geography

Revenue Distribution	Q4 FY25	Q3 FY25	Q4 FY24	YoY Gr%	FY25	FY24	YoY Gr%
Formulations	3,015	3,008	2,476	22%	11,858	9,997	19%
Europe	1,323	1,334	1,236	7%	5,565	4,868	14%
Emerging Markets	1,429	1,366	1,007	42%	5,138	4,091	26%
India	263	308	232	13%	1,155	1,038	11%
APIs	869	812	959	(9%)	3,378	3,260	4%
Other Sales	67	23	37	80%	155	133	17%
Global Sales	3,951	3,843	3,472	14%	15,392	13,390	15%
One Offs #					(74)		
Adjustment* - Ind AS 29*	66	65	140		196	307	
Reported Sales	4,017	3,908	3,612	11%	15,514	13,697	13%



*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

Provision for customer claim on shipments in prior years

SeQuent: Q4FY25 Business Performance

All values in ₹ Mn



Formulations

- ✓ **Europe:** Vaccine opportunity proceeding well
- ✓ **Emerging Markets:** Resumption of Tablet sales
- ✓ **LATAM:** Initiated work on the nutraceutical solution range for commercialization
- ✓ **India:** Ready for 2nd phase of field expansion to enhance market coverage



1,000+
FDFs



90+
Countries



5
Manufacturing
Facilities

API

- ✓ Successfully **cleared audits by key customers**
- ✓ **Vizag** won *Gold – Industrial Safety Excellence Award 2024* by AP FICCI
- ✓ **Mahad** awarded by *National Safety Council of India – Occupational Health & Safety Award 2024*



35
APIs



50+
Countries



2
Manufacturing
facilities



SeQuent: FY25 Business Performance

All values in ₹ Mn



Formulations

- ✓ **Europe:** New product launches & vaccines distribution
- ✓ **Emerging Markets:** EUGMP renewal, volume recovery and timely price hikes
- ✓ **LATAM:** Focus on high margin business, new organisation in Mexico
- ✓ **India:** Expanded field team for better coverage



1,000+
FDFs



90+
Countries



5
Manufacturing
Facilities



35
APIs



50+
Countries



2
Manufacturing
facilities

API

- ✓ **Filed two VMFs** during the year, taking the total count at 35
- ✓ Received **WHO Prequalification** approval for **Albendazole**
- ✓ **Safety Recognition:** Vizag awarded **CII Safety Leadership Gold**; scored **98.5 (A+)** from AP Safety Board
- ✓ **Vizag site received accreditation from JMAFF**, Ministry of Agriculture, Forest and Fisheries, Japan
- ✓ Mahad site recognized for health & occupation safety at National safety council of India



Consolidated Financials

All values in ₹ Mn



Particulars	Q4 FY25	Q3 FY25	Grw QoQ %	Q4 FY24	Grw YoY %
Revenue from Operations	4,017	3,908	2.8%	3,612	11.2%
Material Consumption	(1,997)	(2,025)		(1,945)	
Gross Margin	2,020	1,883	7.3%	1,667	21.2%
%	50.3%	48.2%		46.1%	
Employee Benefit Expenses	(653)	(651)		(577)	
Operating Expenses	(797)	(738)		(679)	
Adj. EBITDA	569	494	15.3%	411	38.7%
%	14.2%	12.6%		11.4%	
ESOP cost	(114)	(102)		(45)	
Exceptional Items	(3)	(3)		(47)	
IndAS 29 Adjustment*	6	5		(20)	
Exchange Gain / (Loss)	0	(52)		(23)	
Other Income	16	59		40	
Finance Cost	(151)	(150)		(124)	
Depreciation & Amortization	(161)	(170)		(165)	
Earnings Before Tax	163	81	100.6%	26	517.4%
Taxes	(59)	(16)		(14)	
Earnings After Tax	103	65	59.3%	13	712.4%
Minority Interest	11	30		22	
Earnings after Minority Interest	93	35	168.6%	(9)	1119%

FY25	FY24	Grw YoY %
15,514	13,697	13.3%
(8,119)	(7,597)	
7,395	6,100	21.2%
47.7%	44.5%	
(2,487)	(2,283)	
(2,915)	(2,748)	
1,993	1,068	86.6%
12.8%	7.8%	
(324)	(222)	
(50)	(174)	
29	(78)	
(80)	(154)	
147	110	
(608)	(481)	
(665)	(615)	
443	(546)	181.1%
(120)	250	
322	(296)	208.9%
104	63	
219	(359)	161.0%





Viyash: Business Update

Viyash: Q4FY25 – Continued Strong Performance on Revenue, Profitability and Cashflows



All values in ₹ Mn


Revenues



Adj. EBITDA¹



Adj. EBITDA margin



Net Debt to LTM Adj. EBITDA¹



Notes: 1. Viyash EBITDA is adjusted for one-time contractual bonus payable to Viyash management
Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Viyash: FY25 – Robust Full-year Performance

All values in ₹ Mn 


Revenues



Adj. EBITDA¹



Adj. EBITDA margin



Net Debt to LTM Adj. EBITDA¹



Financial Performance


Particulars	Q4	Q4	YoY %	Q3	QoQ %	FY25	FY24 ²	YoY %
	FY25	FY24		FY25				
Revenue from Operations	3,708	3,214	15.4%	3,839	-3.4%	14,580	13,110	11.2%
Material Consumption	(1,652)	(1,420)	16.4%	(1,751)	-5.7%	(6,608)	(6,142)	7.6%
Gross Profit	2,056	1,793	17.1%	2,088	1.5%	7,971	6,968	14.4%
%	55.4%	55.8%		54.4%		54.7%	53.2%	
Operating Expenses	(1,405)	(1,464)	-4.0%	(1,439)	-2.4%	(5,490)	(5,332)	3.0%
Foreign Exchange Gain / (Loss)	3	8		36		65	34	
Adj. EBITDA¹	653	338	93.2%	685	-4.5%	2,546	1,671	52.4%
%	17.6%	10.5%		17.8%		17.5%	12.7%	

Note: 1. EBITDA for Viyash is adjusted for ESOP costs, cost for accelerated vesting of warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management

2. Q4 FY24 based on management accounts that have not been subject to limited review by auditors

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Key Updates from Q4FY25



Facility Inspections

- ✓ **3** Regulatory Audits
- ✓ **28** Customer audits



Regulatory Approvals

- ✓ **6 APIs:** USDMF (1), EDMF (3), CN (2)



Launches

- ✓ **3 API**
- ✓ **1 FDFs**



Products Filed

- ✓ **03 APIs:** USDMF (1), CEP (1), EDMF(1)



Validations Completed

- ✓ **3 API + 1 intermédiaire**



R&D Pipeline

- ✓ **25+ Products**

Viyash: Overview (3 key segments)

APIs

- ✓ **70+ commercial products**; 23% CAGR for 10 products over FY22-25 with 58% material margins. Market leader for 6 of those products
- ✓ **200+ customers** across 150+ countries; well diversified revenue base with no customer >15% of revenue
- ✓ **8 plants** with strong regulatory & audit track record. Backward integrated portfolio with cost leadership. 35+ audits over the last 10 years from multiple regulators (USFDA, EU GMP, ANVISA, NMPA)
- ✓ **185+ R&D team**; High EHS compliance (dedicated process safety lab), best in class regulatory & quality teams
- ✓ **Dedicated Oncology facility**
- ✓ Strengthened R&D & BD Team

Strategic Innovator & CDMO

- ✓ **Existing customer base**: 10+ innovators & complex generic customers
- ✓ Supplier to top 10 large generic players
- ✓ Added 10+ development contracts with innovators and complex generic manufacturers in last 2 years

Formulations

- ✓ **Portfolio**: 23 commercial ANDAs
- ✓ **New Portfolio**: 10+ CGTs / NCE-1 / First to File (FTF) products. Focus on complex portfolio
- ✓ **Manufacturing**: New Jersey site; local manufacturing enables US Government & defense business
- ✓ **Integration**: All strategic and large volume products under vertical integration for cost leadership

Merger Update



Q4FY25: Combined Business Performance

Q4 FY25 (For the quarter)	Viyash	+	Sequent Proven Ability In Life Science	=	Combined	YoY Growth % (Combined)
Revenue (INR Mn)	3,708		4,017		7,725	13.2%
Adj. EBITDA ¹ (INR Mn)	653		569		1,222	63.2%
Adj. EBITDA Margin %	17.6%		14.2%		15.8%	+485bps
Net Debt to LTM Adj. EBITDA	0.3x		1.9x		1.0x	

FY25: Combined Business Performance

FY25	Viyash	+	Sequent Proven Ability In Life Science	=	Combined	YoY Growth % (Combined)
Revenue (INR Mn)	14,580		15,514		30,094	12.3%
Adj. EBITDA ¹ (INR Mn)	2,546		1,993		4,539	65.7%
Adj. EBITDA Margin %	17.5%		12.8%		15.1%	+488bps
Net Debt to LTM Adj. EBITDA	0.3x		1.9x		1.0x	

Combined P&L – Snapshot

All values in ₹ Mn

Particulars	Viyash		SeQuent		Combined	
	FY24	FY25	FY24	FY25	FY24	FY25
Revenue from Operations	13,110	14,580	13,697	15,514	26,807	30,094
Material Consumption	(6,142)	(6,608)	(7,597)	(8,119)	(13,739)	(14,727)
Gross Margin	6,968	7,971	6,100	7,395	13,068	15,367
%	53.2%	54.7%	44.5%	47.7%	48.7%	51.1%
Operating Expenses	(5,332)	(5,490)	(5,031)	(5,402)	(10,363)	(10,892)
Operating Exchange Gain / (Loss)	34	65	-	-	34	65
Adjusted EBITDA	1,671	2,546	1,068	1,993	2,739	4,539
%	12.7%	17.5%	7.8%	12.85%	10.2%	15.1%
ESOP cost	(127)	(82)	(222)	(324)	(349)	(406)
Exceptional Items ¹	(58)	(979)	(174)	(50)	(232)	(1,029)
Ind AS 29 Adjustment	-	-	(78)	29	(78)	29
Exchange Gain / (Loss)	-	-	(154)	(80)	(154)	(80)
Other Income	502	182	110	147	612	329
Finance Cost	(332)	(256)	(481)	(608)	(813)	(864)
D&A	(718)	(720)	(539)	(589)	(1,257)	(1,309)
Amortization of Acquisition Intangibles	(935)	(1,003)	(76)	(76)	(1,011)	(1,079)
Profit Before Tax	3	(311)	(546)	443	(543)	132
Taxes	(88)	146	250	-120	162	26
Profit After Tax	(85)	(165)	(296)	322	(381)	157
Adjusted PAT²	640	1,296	(63)	429	591	1,725

Key Notes :

- ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events:
- Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and provision for one-time costs
 - Amortization of acquisition intangibles in Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27

1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses and one-time contractual bonus payable to Viyash management

2. PAT adjusted for Amortization of acquisition intangibles (net of tax) and Exceptional Items

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Combined Balance Sheet & Cash Flow: INR 2.5bn in Free Cash Generation in FY25

All values in ₹ Mn

Balance Sheet	Combined	
	FY24	FY25
Non-Current Assets	23,583	23,062
Fixed Assets	10,592	10,332
Goodwill	7,569	7,961
Other Non-Current Assets	5,422	4,769
Net Current Assets	5,254	8,071
Accounts Receivables	6,604	8,071
Inventories	6,979	6,822
Accounts Payable	4,707	4,995
Net Working Capital	8,876	9,898
Other Net Current Assets	(3,622)	(1,826)
Equity	20,364	24,419
Minority Interest	1,312	1,334
Other Non-Current Liabilities	1,144	700
Net Debt	6,017	4,681
Debt	7,580	6,083
Cash	1,563	1,403

Cash Flow	Combined	
	FY24	FY25
Adj. EBITDA	2,739	4,539
Less: NWC	(1,207)	(580)
Less: Tax	(441)	(479)
Less: Others	312	69
Op. CF	1,402	3,548
Less: Capex	(1,189)	(1,091)
FCF	214	2,457
Add: Proceeds from Sale of Fixed Assets	689	210
Less: Acquisition of Residual Stake in Viyash Subsidiary (Symed) ¹	-	(3,907)
Add: Proceeds from Rights Issue (at Viyash)	-	3,127
Borrowings	495	(1,473)
Less: Interest paid	(929)	(934)
Add: Proceeds from ESOPs	(1)	75
Others	(38)	286
Cash Generation	429	(160)

1. 26% stake acquired in Symed (100% owned subsidiary post transaction) in July 2024

Merger – Process Update

Merger process status update

- CCI approval received
- Stock exchange NOC process underway - scheme under review and final NOC awaited
- Upon receipt of NOC, NCLT filing to be made
- Other regulatory approvals, if any to follow

Expected timelines for the completion of the merger process as indicated to be 12-15 months (from merger announcement in September 2024).

This remains unchanged versus prior quarter as process is well on track as per estimated timelines



Synergy Update

Synergy Planning Process on Track

- ✓ **CCI** approval received
- ✓ Senior management teams have identified & prioritized **synergy areas**
- ✓ **Integration planning workshops** kicked off in Q4FY25
- ✓ **Granular synergy action plan & estimated value** to be presented to board in H1FY26

4 Core synergy areas identified		Synergy Realization Timeline (Months)			
Area	Key Ideation Action Items	Till Merger Approval	0-6	6-12	12+
R&D	<ul style="list-style-type: none"> R&D teams to be co-located; to work collaboratively on NPD & cost improvement QA & Testing to be moved on-site from 3rd party location 				
Manufacturing	<ul style="list-style-type: none"> Utilize available low-cost capacity through the group; action plan created Procurement synergies 				
Sales	<ul style="list-style-type: none"> Leverage key relationships of both companies; outreach & discussion plan prepared 				
Others	<ul style="list-style-type: none"> Assess shared administrative & support functions 				


In advanced stages

We are here

Group Strategy



Key Pillars of our Strategy



API++: Key Differentiators

Products

200+ products in portfolio across animal & human health care. Basket of **high value medium volume** products (**no product > 13%** FY25 API++ Revenue)

Customers & Markets

Well diversified business with **175+ customers** across **150+ markets**; **top 5 customers** accounts for **15%** of FY25 Revenue

Manufacturing

14+ plants with FDA, EU GMP, ANVISA registrations with 15+ cumulative FDA audits

Operating Backbone

200+ R&D resources; invested in analytical team, regulatory and IP setup. **Highly backward integrated** for cost leadership





INR 13.5bn in FY25 Revenue (45% of Combined FY25 Revenue)

Product	% of FY25 API++ Revenue	Market Share (%) ¹	Markets
Product 1	13.0%	61%	USA, Europe, LATAM, RoW
Product 2	9.4%	27%	Europe, LATAM, RoW
Product 3	7.1%	47%	USA, Europe, LATAM, RoW
Product 4	6.0%	50%	Europe, LATAM, ROW
Product 5	3.8%	59%	US, Europe, LATAM, ROW
Product 6	3.6%	50%	Europe, ROW
Product 7	3.4%	38%	USA, Europe, LATAM, RoW
Product 8	3.4%	35%	USA, Europe, LATAM, RoW
Product 9	2.8%	29%	Europe, LATAM, RoW
Product 10	2.4%	60%	US, Europe, LATAM, ROW
Total	56%	46%	

Top 10 products grew at 16% CAGR over FY22-25; 57% Material Margin

1. Source: IMS MAT

API++: Drivers of future growth

	Dimension	Current State of Play	Key growth levers
	Portfolio	<ul style="list-style-type: none">Filed 31 products & validated 22 products in FY25	<ul style="list-style-type: none">Developing oncology focused portfolio across all OEBs35+ products in the pipeline; complex portfolio
	Manufacturing	<ul style="list-style-type: none">220+ cumulative regulatory and customer audits	<ul style="list-style-type: none">Adding (i) spray drying capabilities in high potent manufacturing & (ii) 300KL+ expanding capacity in 2 sites
	R&D	<ul style="list-style-type: none">Dedicated lab set up to handle high potency Cytotoxic products across all OEBsDeveloped and validated 4 complex Generics CDMO projects for 3+ US, EU and Indian based customers	<ul style="list-style-type: none">Focusing on development and supply of differentiated/ hard-to-make Generics projects with Global customers on CDMO model
	Others	<ul style="list-style-type: none">Management team, manufacturing base and R&D infrastructure built out for next phase of growth	<ul style="list-style-type: none">Operating leverage

Global Formulations: Key Differentiators

Wide Portfolio

1,000+ SKUs across multiple segments (gut health, pain management, injectables, etc.) and species

Global Markets

300+ field force across 10 core markets

Leadership position

Top 5 market position in focus segments across multiple large markets like Spain ,Brazil & Turkey

Quality Manufacturing







6 manufacturing facilities, across multiple capabilities (e.g., manufacturing injectables)

INR 15.7 bn in FY25 Revenue (52% of Combined FY25 Revenue)


Market	% of FY25 Formulations Revenue	Sales Team Count
Europe (Animal Health)	36%	
Emerging Markets (Animal Health)	33%	300+
India (Animal Health)	8%	
USA (Human Health)	23%	NA
Total	100%	

Revenue
CAGR of 7%
over FY22-25

Global Formulations: Drivers of future growth

	Dimension	Current State of Play	Key Growth Levers
	Portfolio	<ul style="list-style-type: none"> 1000+ SKUs across multiple species and delivery forms (injectables, orals, supplements) Ready-to-market technical materials for geo-extension of products across markets 	<ul style="list-style-type: none"> Expand key brands globally Opportunistic in-licensing and marketing deals
	Market access	<ul style="list-style-type: none"> Direct presence in 10 countries, 300+ field force Distributor-led presence in 80+ countries Repeatable playbook for market entry – <i>portfolio selection, product registrations, commercial investments, technical marketing, local in-licensing</i> 	<ul style="list-style-type: none"> Market expansion – Scale up India and key markets via investment in Sales team footprint creating a “network effect” New markets - Entering new SEA market; multiple Latam/EU markets open
	Segments	<ul style="list-style-type: none"> Coverage in Production and select Companion Animal therapies Focus on high-growth niches (injectables, pain, gut, supplements) 	<ul style="list-style-type: none"> Strong right to win to expand into complementary segments like dermatology, ophthalmology, oncology etc.
	Innovation and R&D	<ul style="list-style-type: none"> In-house 35+ member R&D team across global sites 22 product launches in the last 3 years 	<ul style="list-style-type: none"> 30+ product strong R&D pipeline Culture of Innovation and ideation built across all levels
	Team	<ul style="list-style-type: none"> Management team fully built out for next phase of growth 	<ul style="list-style-type: none"> Select additions for next phase of growth; operating leverage expected
	M&A	<ul style="list-style-type: none"> Proven M&A playbook – 9 M&A over the last 10 years 	<ul style="list-style-type: none"> Focused M&A to expand products, segments and markets


Strategic Innovator and CDMO business




For details, feel free to contact:

Yoshita Vora


Company Secretary

 +91 22 4111 4777

 investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultant

 abhishek@arunya.co.in

***Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39,
Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana***

Websites: www.sequent.in, www.alivira.co | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.



Thank You

